273 related articles for article (PubMed ID: 31536478)
1. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
4. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
[TBL] [Abstract][Full Text] [Related]
5. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
6. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C
Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174
[TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
9. Malignant Mesothelioma Effusions Are Infiltrated by CD3
Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
[TBL] [Abstract][Full Text] [Related]
10. Systemic and local immunosuppression in patients with high-grade meningiomas.
Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
[TBL] [Abstract][Full Text] [Related]
11. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
[TBL] [Abstract][Full Text] [Related]
12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
14. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
[TBL] [Abstract][Full Text] [Related]
15. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
16. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
Ernst D; Williams BA; Wang XH; Yoon N; Kim KP; Chiu J; Luo ZJ; Hermans KG; Krueger J; Keating A
Blood Cancer J; 2019 Jan; 9(2):6. PubMed ID: 30647406
[TBL] [Abstract][Full Text] [Related]
17. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
Hamilton G; Rath B
Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
19. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
Jochems C; Hodge JW; Fantini M; Fujii R; Morillon YM; Greiner JW; Padget MR; Tritsch SR; Tsang KY; Campbell KS; Klingemann H; Boissel L; Rabizadeh S; Soon-Shiong P; Schlom J
Oncotarget; 2016 Dec; 7(52):86359-86373. PubMed ID: 27861156
[TBL] [Abstract][Full Text] [Related]
20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]